This document provides a short summary of this study for a general audience. You can
find more information in the scientific summaries of the study. Links to those
summaries are provided at the end of this document.
Study names
Short Title: A study to compare triple therapy (fluticasone furoate/umeclidinium/
vilanterol) with tiotropium alone in patients with chronic obstructive pulmonary
disease.
Full Scientific Title: A Phase IV, 12 week, randomised, double-blind, double-dummy
study to compare single inhaler triple therapy, fluticasone furoate/umeclidinium/
vilanterol, with tiotropium monotherapy based on lung function and symptoms in
participants with chronic obstructive pulmonary disease.
Study Number: 207626
Who sponsored this study?
GlaxoSmithKline (GSK)
GSK Clinical Support Help Desk
Website: clinicalsupporthd.gsk.com/contact.html
Email: GSKClinicalSupportHD@gsk.com
General information about the clinical study
When was this study done?
The study started in March 2018 and ended in July 2019.
What was the main objective of this study?
Chronic obstructive pulmonary disease (COPD) is a long-term disease of the lungs that
makes it hard to breathe and gets worse over time. For patients with COPD, inhaled
medicines are an important part of treatment. An inhaler is a handheld device that
delivers medicine(s) to the lungs.
Use of the data and information contained in this Document is unrestricted, provided that it may not
be used in applications by others for regulatory approval of a product. While not required, when using
these data, we ask that proper credit or attribution of GSK as the source of the data be given. GSK
disclaims liability for all uses of the data by users of this Document, to the fullest extent permitted by
applicable law. No trademark, patent, or regulatory/data exclusivity rights held by GSK are waived,
licensed or otherwise affected.